Trial · NCT03296527
Outcomes61
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
41 to 60 of 61
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Change From Baseline in Clinical Chemistry Parameter: Direct Bilirubin, Bilirubin, Creatinine, Urate | From screening up to end-of-trial (approximately 5.5 months) | The safety analysis set was defined as all randomized and exposed participants. Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | umol/L | MEAN |
| SECONDARY | Proportion of Subjects With Markedly Abnormal Changes of Clinical Chemistry: Alanine Aminotransferase, Aspartate Aminotransferase, Bicarbonate, Calcium, Phosphate | End-of-stimulation visit and end-of-trial visit | The safety analysis set was defined as all randomized and exposed participants. Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | percentage of participants | NUMBER |
| SECONDARY | Change From Baseline in Haematology Parameter: Erythrocytes | From screening up to end-of-trial (approximately 5.5 months) | The safety analysis set was defined as all randomized and exposed participants. Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | 10^12 cells/L | MEAN |
| SECONDARY | Change From Baseline in Haematology Parameters: Leukocytes and Platelets | From screening up to end-of-trial (approximately 5.5 months) | The safety analysis set was defined as all randomized and exposed participants. Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | 10^9 cells/L | MEAN |
| SECONDARY | Change From Baseline in Haematology Parameter: Haemoglobin | From screening up to end-of-trial (approximately 5.5 months) | The safety analysis set was defined as all randomized and exposed participants. Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | g/L | MEAN |
| SECONDARY | Change From Baseline in Haematology Parameter: Haematocrit | From screening up to end-of-trial (approximately 5.5 months) | The safety analysis set was defined as all randomized and exposed participants. Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | Ratio | MEAN |
| SECONDARY | Change From Baseline in Haematology Parameter: Erythrocyte Mean Corpuscular Volume | From screening up to end-of-trial (approximately 5.5 months) | The safety analysis set was defined as all randomized and exposed participants. Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | Femtoliters | MEAN |
| SECONDARY | Change From Baseline in Haematology Parameter: Erythrocyte Mean Corpuscular Haemoglobin | From screening up to end-of-trial (approximately 5.5 months) | The safety analysis set was defined as all randomized and exposed participants. Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | picogram | MEAN |
| SECONDARY | Change From Baseline in Haematology Parameter: Erythrocyte Mean Corpuscular Haemoglobin Concentration | From screening up to end-of-trial (approximately 5.5 months) | The safety analysis set was defined as all randomized and exposed participants. Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | mmol/L | MEAN |
| SECONDARY | Change From Baseline in Haematology Parameters: Basophils/Leukocytes, Eosinophils/Leukocytes, Lymphocytes/Leukocytes, Monocytes/Leukocytes and Neutrophils/Leukocytes | From screening up to end-of-trial (approximately 5.5 months) | The safety analysis set was defined as all randomized and exposed participants. Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | percentage | MEAN |
| SECONDARY | Proportion of Subjects With Markedly Abnormal Changes of Haematology Parameters: Leukocytes, Lymphocytes/Leukocytes | End-of-stimulation visit and end-of-trial visit | The safety analysis set was defined as all randomized and exposed participants. Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | percentage of participants | NUMBER |
| SECONDARY | Number of Immune-related Adverse Events | From screening up to end-of-trial (approximately 5.5 months) | The safety analysis set was defined as all randomized and exposed participants. Participants were analyzed according to actual treatment received. | events | NUMBER |
| SECONDARY | Frequency of Injection Site Reactions | End-of-stimulation (up to 20 stimulation days) | The safety analysis set was defined as all randomized and exposed participants. Participants were analyzed according to actual treatment received. | percentage of participants | NUMBER |
| SECONDARY | Intensity of Injection Site Reactions | End-of-stimulation (up to 20 stimulation days) | The safety analysis set was defined as all randomized and exposed participants. Participants were analyzed according to actual treatment received. | percentage of participants | NUMBER |
| SECONDARY | Proportion of Subjects With Treatment-induced Anti-FSH Antibodies, Overall as Well as With Neutralizing Capacity | Up to 28 days after end of the stimulation period | The safety analysis set was defined as all randomized and exposed participants. Participants were analyzed according to actual treatment received. | percentage of participants | NUMBER |
| SECONDARY | Intensity of Immune-related Adverse Events | From screening up to end-of-trial (approximately 5.5 months) | The safety analysis set was defined as all randomized and exposed participants. Participants were analyzed according to actual treatment received. | events | NUMBER |
| SECONDARY | Proportion of Subjects With Cycle Cancellations Due to an Adverse Event, Including Immune-related Adverse Events, or Due to Technical Malfunctions of the Administration Pen | Up to 20 stimulation days | The FAS was defined as all randomized and exposed participants. Participants were analyzed according to randomized treatment. | percentage of participants | NUMBER |
| SECONDARY | Proportion of Subjects With Late OHSS | After 9 days post triggering of final follicular maturation | The safety analysis set was defined as all randomized and exposed participants. Participants were analyzed according to actual treatment received. | percentage of participants | NUMBER |
| SECONDARY | Proportion of Participants With Multi-fetal Gestation | End-of-trial | The FAS was defined as all randomized and exposed participants. Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | percentage of participants | NUMBER |
| SECONDARY | Proportion of Participants With Early Pregnancy Losses | End-of-trial | The safety analysis set was defined as all randomized and exposed participants. Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | percentage of participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03296527/outcomes?page=3